Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials

INTRODUCTION: Dalbavancin is a lipoglycopeptide antibiotic approved as a single- and two-dose regimen for adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms. We present nephrotoxicity rates for patients with ABSSSI who received dalba...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, Pedro L., Rappo, Urania, Mas Casullo, Veronica, Akinapelli, Karthik, McGregor, Jennifer S., Nelson, Jennifer, Nowak, Michael, Puttagunta, Sailaja, Dunne, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955009/
https://www.ncbi.nlm.nih.gov/pubmed/33515414
http://dx.doi.org/10.1007/s40121-021-00402-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955009/
https://www.ncbi.nlm.nih.gov/pubmed/33515414
http://dx.doi.org/10.1007/s40121-021-00402-0

Ejemplares similares